01/15
Headlines

John Meady

Why Making Dramatic Moves: Dean Foods Company (NYSE:DF), Baidu Inc (ADR) (NASDAQ:BIDU), Merck & Co. Inc. (NYSE:MRK), Coffee Holding Company (NASDAQ:JVA), JRN

John Meady03 mins

Dean Foods Company (NYSE:DF), the largest U.S. milk processor, forecast its first quarterly adjusted profit in a year, citing cost cuts and a steep fall in butterfat prices. The company, whose shares rose 13.7 percent yesterday to close at $16.40, also reported an adjusted third-quarter loss that was smaller than expected. This was the first…

Read More

Today’s Watch List: EOG Resources, Inc. (NYSE:EOG), QUALCOMM, Inc. (NASDAQ:QCOM), Sonic Corp. (NASDAQ:SONC), Furmanite Corporation (NYSE:FRM), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

John Meady03 mins

EOG Resources (NYSE:EOG) was upgraded by analysts at Bernstein to an “outperform” rating in a note issued to investors on Monday. EOG Resources, Inc. (NYSE:EOG) belongs to Basic Materials sector. Its net profit margin is 15.50% and weekly performance is 4.73%. On last trading day company shares ended up $99.55. EOG Resources, Inc. (NYSE:EOG) distance…

Read More

Stocks in Focus: Proteon Therapeutics, Inc. (NASDAQ:PRTO), Pandora Media Inc (NYSE:P), KCAP Financial, Inc. (NASDAQ:KCAP), Tarena International, Inc. (NASDAQ:TEDU), EMCORE Corporation (NASDAQ:EMKR)

John Meady02 mins

Proteon Therapeutics (NASDAQ:PRTO) Insider James E. Flynn bought 691,713 shares of the company’s stock in a transaction dated Monday, October 27th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $6,917,130.00. Proteon Therapeutics, Inc. (NASDAQ:PRTO) belongs to Healthcare sector. Its weekly performance is 2.30%. On last trading…

Read More

Regeneron and Partner Announced Positive First Trial Results of Odyssey

John Meady02 mins

Regeneron and its partner Sanofi announced positive results in the first trial of their extensive Phase III ODYSSEY program (12 trials in total) for alirocumab (REGN-727), which targets PCSK9 to lower LDL (or “bad”) cholesterol. Alirocumab showed a 47.2% reduction in LDL levels from baseline over 24 weeks in patients with primary hypercholesterolemia and moderate…

Read More